In our study, 41 patients would tolerate the second-line or third-line treatment after the chronic symptoms improved, compared with 35 patients in the control group, which indicated that FJQR increased the probability of HER-2 negative GC patients receiving post-line treatment. The gene discussed is ERBB2; the disease is gastric cancer.